Multivariate Cox regression
| Stage group | Parameter | Numerator | Reference | Hazard ratio (95% CI) | P value |
| Progression-free survival | |||||
| Early-stage | Age at diagnosis | 0.99 (0.96 to 1.03) | 0.6911 | ||
| C/C+E | Yes | No | 1.14 (0.61 to 2.12) | 0.6756 | |
| Radiation* | Yes | No | 0.68 (0.33 to 1.38) | 0.2878 | |
| Chemotherapy cycles† | ≥5 cycles | <5 cycles | 1.05 (0.57 to 1.92) | 0.8826 | |
| Tumor size | >2 cm–≤4 cm | ≤2 cm | 3.57 (1.78 to 7.14) | 0.0003 | |
| Histology | Pure | Mixed | 1.54 (0.87 to 2.74) | 0.1392 | |
| Surgery‡ | Yes | No | 2.09 (0.74 to 5.91) | 0.1634 | |
| Locally advanced | Age at diagnosis | 1 (0.99 to 1.02) | 0.5877 | ||
| C/C+E | Yes | No | 0.75 (0.5 to 1.14) | 0.1771 | |
| Nodal positivity§ | Positive | Negative | 1.46 (1.01 to 2.12) | 0.0434 | |
| Chemotherapy cycles† | ≥5 cycles | <5 cycles | 0.96 (0.63 to 1.45) | 0.8401 | |
| Histology | Pure | Mixed | 1.24 (0.86 to 1.8) | 0.2491 | |
| Tumor size | >4 cm | ≤4 cm | 1.11 (0.76 to 1.62) | 0.5740 | |
| Advanced | Age at diagnosis | 1.01 (0.99 to 1.04) | 0.2265 | ||
| C/C+E | Yes | No | 0.96 (0.51 to 1.82) | 0.9014 | |
| Radiation* | Yes | No | 0.35 (0.19 to 0.65) | 0.0009 | |
| Nodal positivity | Positive | Negative | 1.66 (0.96 to 2.87) | 0.0689 | |
| Chemotherapy cycles† | ≥5 cycles | <5 cycles | 1.14 (0.63 to 2.05) | 0.6702 | |
| Histology | Pure | Mixed | 1.28 (0.62 to 2.66) | 0.5097 | |
| Tumor size | >4 cm | ≤4 cm | 1.19 (0.64 to 2.2) | 0.5826 | |
| Overall survival | |||||
| Early-stage | Age at diagnosis | 0.99 (0.95 to 1.03) | 0.6187 | ||
| C/C+E | Yes | No | 0.86 (0.44 to 1.7) | 0.6674 | |
| Radiation* | Yes | No | 0.57 (0.26 to 1.29) | 0.1792 | |
| Chemotherapy cycles† | ≥5 cycles | <5 cycles | 0.92 (0.44 to 1.93) | 0.8255 | |
| Tumor size | >2 cm -≤4 cm | ≤2 cm | 2.52 (1.11 to 5.68) | 0.0265 | |
| Histology | Pure | Mixed | 1.39 (0.71 to 2.75) | 0.3382 | |
| Surgery‡ | Yes | No | 1.9 (0.48 to 7.51) | 0.3627 | |
| Locally advanced | Age at diagnosis | 1.01 (0.99 to 1.02) | 0.2462 | ||
| C/C+E | Yes | No | 0.75 (0.49 to 1.15) | 0.1859 | |
| Nodal positivity§ | Positive | Negative | 1.55 (1.06 to 2.28) | 0.0248 | |
| Chemotherapy cycles† | ≥5 cycles | <5 cycles | 0.83 (0.53 to 1.3) | 0.4235 | |
| Pure vs mixed | Pure | Mixed | 1.44 (0.99 to 2.12) | 0.0592 | |
| Tumor size | T3 (>4 cm) | ≤4 cm | 1.03 (0.7 to 1.51) | 0.8975 | |
| Advanced | Age at diagnosis | 1.02 (0.99 to 1.04) | 0.1675 | ||
| C/C+E | Yes | No | 0.33 (0.17 to 0.63) | 0.0008 | |
| Radiation* | Yes | No | 0.32 (0.17 to 0.6) | 0.0004 | |
| Nodal positivity | Positive | Negative | 1.38 (0.82 to 2.34) | 0.2263 | |
| Chemotherapy cycles† | ≥5 cycles | <5 cycles | 0.77 (0.45 to 1.33) | 0.3550 | |
| Histology | Pure | Mixed | 1.06 (0.54 to 2.07) | 0.8605 | |
| Tumor size | >4 cm | ≤4 cm | 3.12 (1.56 to 6.24) | 0.0013 | |
| Survival from first recurrence or progression | |||||
| Early-stage | Age at diagnosis | 0.98 (0.94 to 1.02) | 0.3703 | ||
| Texas cocktail | Yes | No | 0.81 (0.33 to 1.98) | 0.6472 | |
| Curative radiation | Yes | No | 0.8 (0.34 to 1.9) | 0.6086 | |
| Chemotherapy cycles† | ≥5 cycles | <5 cycles | 0.75 (0.34 to 1.66) | 0.4757 | |
| Tumor size | >2 cm–≤4 cm | ≤2 cm | 0.72 (0.32 to 1.64) | 0.4312 | |
| Histology | Pure | Mixed | 0.97 (0.46 to 2.04) | 0.9345 | |
| Surgery‡ | Yes | No | 0.35 (0.07 to 1.74) | 0.2010 | |
| Locally advanced | Age at diagnosis | 1.01 (1 to 1.02) | 0.1866 | ||
| Texas cocktail | Yes | No | 0.74 (0.44 to 1.26) | 0.2698 | |
| Nodal positivity | Positive | Negative | 1.22 (0.82 to 1.82) | 0.3235 | |
| Chemotherapy cycles† | ≥5 cycles | <5 cycles | 0.74 (0.49 to 1.11) | 0.1447 | |
| Histology | Pure | Mixed | 2.00 (1.35 to 2.98) | 0.0006 | |
| Tumor size | T3 (>4 cm) | ≤4 cm | 1.08 (0.71 to 1.63) | 0.7217 | |
| Advanced | Age at diagnosis | 1.01 (0.98 to 1.03) | 0.5367 | ||
| Texas cocktail | Yes | No | 0.52 (0.27 to 0.99) | 0.0454 | |
| Radiation* | Yes | No | 0.44 (0.22 to 0.89) | 0.0228 | |
| Nodal positivity | Positive | Negative | 0.91 (0.52 to 1.57) | 0.7324 | |
| Chemotherapy cycles† | ≥5 cycles | <5 cycles | 0.78 (0.39 to 1.59) | 0.5005 | |
| Histology | Pure | Mixed | 0.94 (0.48 to 1.85) | 0.8659 | |
| Tumor size | >4 cm | ≤4 cm | 3.18 (1.56 to 6.46) | 0.0014 | |
No C/C+E is defined as no chemotherapy or other chemotherapy agents.
Texas cocktail is defined as a combination of topotecan, paclitaxel, and bevacizumab.
*Curative radiation therapy with or without chemotherapy. No curative radiation therapy is defined as chemotherapy alone or with palliative radiation therapy.
†Chemotherapy cycles is defined as the total number of cycles of C/C+E (concurrently with radiation therapy and as additional chemotherapy).
‡Surgery is defined as a simple hysterectomy, radical hysterectomy, or radical trachelectomy. No surgery is defined as not having had any of those three types of procedure.
§Nodal positivity (pelvic and/or para-aortic) based on pathology report for patients who underwent surgery (sentinel lymph node biopsy and/or pelvic lymphadenectomy and/or para-aortic lymphadenectomy) and images for patients who did not undergo surgery.
C/C+E, cisplatin/carboplatin+etoposide.